Business Context and Reporting Period
Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Pediatrix is a leading provider of physician services, specializing in neonatal, maternal-fetal, pediatric subspecialty, and anesthesia care. As of December 31, 2007, the company's national network included 1,072 affiliated physicians operating in 32 states and Puerto Rico. The company manages clinical activities in over 257 Neonatal Intensive Care Units (NICUs).
Strategic Shift: In December 2007, the company signed a definitive agreement to sell its newborn metabolic screening laboratory business, classifying it as discontinued operations to focus resources on physician services expansion.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Net Patient Service Revenue | $917.6 million | $804.7 million |
| Net Income | $142.7 million | $124.5 million |
| Diluted EPS | $2.86 | $2.52 |
| Operating Margin | 24.1% | 24.2% |
| Cash and Cash Equivalents | $102.8 million | $69.6 million |
| Working Capital | $99.2 million | $80.3 million |
| Long-Term Debt | $0.9 million | $0.9 million |
| Line of Credit Availability | $206.7 million | N/A |
Note: The company had no outstanding principal balance on its $225 million revolving line of credit as of December 31, 2007, though $18.3 million was utilized for letters of credit.
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 14.0% ($112.9 million) year-over-year. This was driven by $42.2 million from acquisitions and $70.7 million from same-unit growth (9.3%). Same-unit growth was attributed to higher patient volumes (4.2% increase in NICU patient days) and improved reimbursement rates, particularly from the Texas Medicaid program.
- Expense Increases: Practice salaries and benefits rose 14.4% ($67.1 million) due to new physician hires for acquisitions, increased incentive compensation, and costs related to stock option measurement date revisions (409A tax obligations).
- Acquisitions: The company completed ten acquisitions in 2007, including its first anesthesia practice (Fairfax Anesthesiology Associates), expanding its service lines beyond neonatal and maternal-fetal care.
- Share Repurchases: The company completed a $100 million share repurchase program in November 2007, purchasing approximately 1.6 million shares. A new $100 million program was authorized in December 2007.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2008 Plans: Management plans to invest $70 million to $75 million in acquisitions within historical specialties (neonatal, maternal-fetal, cardiology) and expects to complete one or more anesthesia acquisitions.
- Discontinued Operations: The sale of the newborn metabolic screening laboratory is expected to close in the first quarter of 2008.
- Effective Tax Rate: The company anticipates an effective tax rate of approximately 39.25% for 2008.
Risks and Contingencies
- Government Investigations: The SEC and U.S. Attorney's Office are conducting formal investigations into the company's historical stock option granting practices. The company incurred significant professional fees and costs related to 409A tax obligations in 2007.
- Corporate Integrity Agreement: The company is subject to a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) following a 2006 settlement regarding billing practices. Failure to comply could result in exclusion from federal healthcare programs.
- Regulatory Environment: The company faces risks related to changes in Medicaid/Medicare reimbursement rates, fraud and abuse laws (False Claims Act, Stark Law), and antitrust scrutiny.
- Legal Proceedings: A shareholder derivative lawsuit regarding stock option practices was settled in January 2008 for $1.5 million in legal fees (subject to court approval), which the company expects to be covered by insurance.
Investor Verification Checklist
- Stock Option Investigation Status: Verify the outcome of the SEC and U.S. Attorney's Office investigations into historical stock option practices and any potential restatements or penalties.
- Discontinued Operations Sale: Confirm the closing date and final proceeds from the sale of the newborn metabolic screening laboratory business.
- Reimbursement Trends: Monitor changes in Medicaid reimbursement rates, specifically in Texas (28% of revenue), and the impact of managed care contracting on net patient service revenue.
- Acquisition Integration: Assess the financial performance and integration of the ten physician groups acquired in 2007, particularly the new anesthesia practice.
- Corporate Integrity Compliance: Review the company's ongoing compliance with the OIG Corporate Integrity Agreement to ensure no risk of exclusion from federal programs.